NCT01541943

Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 356 (actual)
• Sponsor: HanAll BioPharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia

Conditions

• Essential Hypertension
• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	Atorvastatin	Once daily, administered orally, 8 week
DRUG	Losartan	Once daily, administered orally, 8 week
DRUG	Placebo	Once daily, administered orally, 8 week
DRUG	HL-040XC	Once daily, administered orally, 8 week

Timeline

• Start date: 2012-03-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2012-03-01
• Last updated: 2015-09-23

Locations

1 site across 1 country: South Korea